120 Participants Needed

Liquid Biomarkers for Prostate Cancer

(ARCTIC Trial)

Recruiting at 2 trial locations
MR
KS
MA
Overseen ByMonika Anand, PhD
Age: 18+
Sex: Male
Trial Phase: Academic
Sponsor: Duke University
Must be taking: AR inhibitors
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to predict how well men with metastatic castration-resistant prostate cancer respond to standard hormonal therapies. Researchers seek to determine if certain genes or proteins in the bloodstream, known as biomarkers, can indicate which treatments will be most effective. Blood samples and a previous tumor biopsy from participants will be analyzed for these biomarkers. This study suits men whose prostate cancer has spread, whose disease has progressed despite certain hormone therapies, and who plan to start new hormone treatments soon. As a Phase 2 trial, it measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to important research.

Why are researchers excited about this trial?

Researchers are excited about the ARCTIC trial because it seeks to uncover why some prostate cancer treatments eventually stop working. Unlike current options that focus on treating cancer directly, this study uses liquid biomarkers to understand resistance to androgen receptor signaling inhibitors (ARSIs). By detecting changes in the cancer cells' behavior through a simple blood test, scientists hope to tailor treatments more effectively and improve long-term outcomes for patients. This approach could lead to personalized therapy strategies and potentially extend the effectiveness of existing treatments.

Who Is on the Research Team?

AA

Andrew Armstrong, MD

Principal Investigator

Duke University

Are You a Good Fit for This Trial?

Inclusion Criteria

Your PSA levels have been rising consistently for at least 2 weeks.
Your PSA level must be at least 1.0 ng/dl before you can join the study.
You can understand and are willing to sign a document saying you agree to take part in the study.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Standard of Care Treatment

Participants receive standard of care treatment for metastatic castration resistant prostate cancer while being monitored for circulating tumor cells and biomarkers

Up to 3 years

Follow-up

Participants are monitored for safety and effectiveness after treatment, including progression-free survival and overall survival

Up to 3 years

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Duke University

Lead Sponsor

Trials
2,495
Recruited
5,912,000+

Memorial Sloan Kettering Cancer Center

Collaborator

Trials
1,998
Recruited
602,000+

University of Wisconsin, Madison

Collaborator

Trials
1,249
Recruited
3,255,000+